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Abstract 20 
The cholinergic enzyme acetylcholinesterase (AChE) and the catalytic component of the 21 
γ-secretase complex, presenilin-1 (PS1), are known to interact.  In this study, we 22 
investigate the consequences of AChE-PS1 interactions, particularly the influence of 23 
AChE in PS1 levels and γ-secretase activity.  PS1 is able to co-immunoprecipitate all 24 
AChE variants (AChE-R and AChE-T) and molecular forms (tetramers and light 25 
subunits) present in the human brain.  Over-expression of AChE-R or AChE-T, or their 26 
respective inactive mutants, all trigger an increase in PS1 protein levels.  The AChE 27 
specie capable of triggering the biggest increase in PS1 levels is a complex of AChE 28 
with the membrane anchoring subunit proline-rich membrane anchor (PRiMA), which 29 
restricts the localization of the resulting AChE tetramer to the outer plasma membrane.  30 
Incubation of cultured cells with soluble AChE demonstrates that AChE is able to 31 
increase PS1 at both the protein and transcript levels.  However, the increase of PS1 32 
caused by soluble AChE is accompanied by a decrease in γ-secretase activity as shown 33 
by the reduction of the processing of the β-amyloid precursor protein.  This inhibitory 34 
effect of AChE on γ-secretase activity was also demonstrated by directly assessing 35 
accumulation of CTF-APP in cell-free membrane preparations incubated with AChE.  36 
Our data suggest that AChE may function as an inhibitor of γ-secretase activity. 37 
38 
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Introduction  39 
Acetylcholinesterase (AChE) is a key enzyme in the cholinergic nervous system. Due to 40 
its physiological role of hydrolyzing acetylcholine and supporting neurotransmission, 41 
this enzyme has been extensively investigated and targeted for pharmacological 42 
intervention. In Alzheimer’s disease (AD), the loss of forebrain cholinergic neurons is 43 
accompanied by a progressive decline in acetylcholine [1,2]. Deficits in cholinergic 44 
function most likely contribute to AD symptoms, affecting cognition, behaviour and 45 
daily living activities.  Although changes in other elements of the cholinergic system 46 
[3,4] are also involved in AD, current AD therapy is mostly focused on inhibitors of 47 
AChE [5,6]. Thus, randomized clinical trials have demonstrated the efficacy of AChE 48 
inhibitors across a wide range of AD severity [7]. 49 
Many studies suggest that AChE could have alternative functions unrelated to 50 
cholinergic neurotransmission [8-12], or its catalytic activity [13-15]. AChE exists as 51 
different variants derived from alternative RNA splicing, generating different 52 
polypeptide encoding transcripts with the same catalytic domain but distinct C-terminal 53 
peptides, which determine the ability of the molecule to form oligomers [16]. These 54 
different transcripts may also influence protein-protein interactions. In the brain, the 55 
major T-transcript encodes subunits which produce monomeric (G1) and tetrameric (G4, 56 
the cholinergic species) AChE forms; while the R-transcript, that is normally present at 57 
low levels, encodes monomeric soluble subunits [17]. The particular subcellular 58 
distribution of each AChE species allows for its interaction with specific proteins.  59 
Brain accumulation of the β-amyloid peptide (Aβ) is a critical feature of AD 60 
pathogenesis. Aβ is the main component of extracellular amyloid plaques and is 61 
generated by processing of the larger transmembrane β-amyloid precursor protein 62 
(APP) [18,19], by the successive action of two proteolytic enzymes, β-secretase and γ-63 
secretase [20]. We have previously identified presenilin-1 (PS1), the active component 64 
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of the γ-secretase complex [21], as an interacting protein of AChE [22]. We have also 65 
shown that genetic modulation of AChE expression influences PS1 levels [23]. 66 
In this study, we further explore the consequences of AChE-PS1 interactions. 67 
We investigate which AChE variant and molecular form influences PS1 levels and if the 68 
AChE enzymatic activity is responsible for modulating PS1 expression. Finally we 69 
address whether altered levels of PS1, triggered by AChE, induce changes in γ-secretase 70 
activity. 71 
72 
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Material and methods  73 
Cell Cultures 74 
Chinese Hamster Ovary (CHO) cells were grown in D-MEM+GlutaMAX™-I 75 
(Dulbecco’s Modified Eagle medium; Gibco®, Life technologies Paisley, UK) 76 
supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% 77 
penicillin/streptomycin solution (P/S; 100 U/mL) (Gibco).  Cells were seeded at a 78 
density of 8×105 cells on 35 mm tissue culture dishes and were transfected the 79 
following day with plasmid cDNA using Lipofectamine™ 2000 (Invitrogen™, Life 80 
technologies Paisley, UK) according to the manufacturer's instructions. The plasmids 81 
employed encoded either human AChE-T (4µg) or AChE-R (1µg) under the 82 
cytomegalovirus (CMV) promoter-enhancer (a generous gift from Dr. H. Soreq, The 83 
Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel). The 84 
PCI “empty” vector (Promega, Madison, USA) served as negative control. After 48 85 
hours of transfection, cells were washed with phosphate-saline buffer (PBS) and 86 
resuspended in 120 µL ice-cold extraction buffer: 50 mM Tris-HCl, pH 7.4 / 150 mM 87 
NaCl / 5 mM EDTA / 1% (w/v) Nonidet P-40 / 0.5% (w/v) Triton X-100 supplemented 88 
with a cocktail of protease inhibitors. Cell lysates were then sonicated and centrifuged 89 
at 70,000×g at 4 ºC for 1 hour. The supernatants were collected and frozen at -80ºC 90 
until biochemical analysis. Alternatively, AChE-T and AChE-R were over-expressed in 91 
SH-SY5Y neuroblastoma cells, grown as described elsewhere [23]. 92 
To determine if localization of AChE in the plasma membrane influences PS1 93 
levels, CHO cells were seeded at a density of 6×105 cells on 35 mm tissue culture dishes 94 
and transfected with 2µg of AChE-T cDNA, with or without 2µg of PRiMA plasmid 95 
cDNA using Lipofectamine™ 2000. The cDNA encoding the mouse PRiMA isoform I 96 
tagged with an HA epitope (YPYDVPDYA) inserted before the stop codon at the C-97 
terminus [24], was a generous gift from Dr. K.W.K. Tsim (The Hong Kong University 98 
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of Science and Technology, Hong Kong, China). The cells were collected for analysis 99 
48 hours after the transfection.  100 
To estimate the AChE activity at the plasma membrane, CHO cells previously 101 
transfected with AChE-T cDNA (2µg) with or without 2µg of PRiMA plasmid cDNA, 102 
were treated with the AChE inhibitor tacrine, 10µM (Sigma-Aldrich, St. Louis, MO, 103 
USA). Forty-eight hours after transfection, cells were washed with PBS and intact 104 
cultured cells were measured for AChE activity using a modiﬁed microassay version of 105 
the colorimetric Ellman’s method [25]. 106 
CHO cells stably overexpressing wild-type human PS1 and wild-type APP 107 
(CHO-PS70, a generous gift from Dr. D. Selkoe, Brigham and Women’s Hospital, 108 
Boston; see ref. 26), were grown in Opti-MEM® (Gibco) containing 10% FBS, 1% P/S 109 
and additionally supplemented with 200 µg/ml G418 and 2.5 µg/ml Puromycin (Sigma-110 
Aldrich). These cells were treated with soluble AChE from Electrophorus electricus 111 
(eel-AChE; Sigma-Aldrich) or vehicle (PBS) for 18 hours, solubilized, and C-terminal 112 
fragments of APP (CTF-APP) quantified by Western blot, and PS1 transcript levels by 113 
quantitative RT-PCR (qRT-PCR). 114 
 115 
Generation of inactive catalytic mutants of AChE 116 
Catalytically inactive species of AChE-R and AChE-T were generated by site-directed 117 
mutagenesis using the QuickChangeTM site directed mutagenesis Kit (Stratagene, La 118 
Jolla, CA, USA) according to the manufacturer’s protocol. AChE activity was removed 119 
in the plasmid cDNA of both active AChE-R and AChE-T by replacing the centre 120 
active serine200 with valine [27].  121 
Inactive mutants (imAChE-T or imAChE-R; 3µg of the cDNAs) were 122 
overexpressed in CHO cells using the Lipofectamine™ 2000 protocol. Cells were 123 
harvested and solubilized after 48 hours. Protein AChE over-expression was assessed 124 
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by Western blot, while the inactive character of the mutants was determined by 125 
measuring AChE activity levels.  126 
 127 
Human brain samples 128 
Samples of adult brain prefrontal cortex from non-demented subjects (three cases, 2 129 
females and 1 male, 58 ±3 years) were obtained from the Banco de Tejidos, Fundación 130 
CIEN (Madrid, Spain). Tissues stored at -80°C were thawed gradually at 4°C and small 131 
pieces of prefrontal cortex were homogenized (10% w/v) in ice-cold 50 mM Tris-HCl 132 
(pH 7.4)-500 mM NaCl-5 mM EDTA-1% (w/v) Nonidet P-40-0.5% (w/v) Triton X-100 133 
supplemented with a cocktail of protease inhibitors. The homogenates were sonicated 134 
and centrifuged at 70,000×g at 4°C for 1 hour; the supernatant was collected, aliquoted 135 
and frozen at -80°C until use. This study was approved by the local ethics committees 136 
and carried out in accordance with the Declaration of Helsinki. 137 
 138 
AChE enzyme assay and protein determination 139 
A modiﬁed microassay version of the colorimetric Ellman’s method was used to 140 
measure AChE [25]. One mU of AChE activity was defined as the number of nmoles of 141 
acetylthiocholine hydrolyzed per minute at 22°C. Total protein concentrations were 142 
determined using the BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 143 
 144 
145 
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Analysis of AChE molecular forms  146 
Molecular forms of AChE were separated according to their sedimentation coefficients 147 
by ultracentrifugation on continuous 5% to 20% (w/v) sucrose gradients containing 148 
0.5% (w/v) Triton X 100, as previously described [25,28]. Enzymes of known 149 
sedimentation coefﬁcient, bovine liver catalase (11.4S) and calf intestinal alkaline 150 
phosphatase (6.1S) were used in the gradients to identify individual AChE forms (G4 = 151 
tetramers; G2 =dimers; G1 =monomers). 152 
 153 
Preparation of membrane fractions and γ-secretase activity assay 154 
Alternatively, for analysis of γ-secretase activity cell membrane preparations were used 155 
[29]. CHO-PS70 cells were washed in PBS, harvested and homogenized using a 156 
mechanical pestle homogenizer in buffer containing 10 mM KCl and 10 mM HEPES, 157 
pH 7.0, supplemented with a protease inhibitor cocktail. The cell homogenates were 158 
centrifuged at 1,000×g for 10 min, and the post-nuclear supernatant was obtained after 159 
centrifugation at 100,000×g for 1 hour. Membrane fractions were resuspended in buffer 160 
containing 20 mM Hepes pH 7.0, 150 mM NaCl, 5 mM EDTA and a protease inhibitor 161 
cocktail. Protein concentration was measured by the BCA Protein Assay Kit (Thermo 162 
Scientific) and maintained at 3–5 mg/ml. The samples were incubated in the absence or 163 
presence of eel-AChE (Sigma-Aldrich) or the γ-secretase inhibitor DAPT, N-[N-(3,5-164 
difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (Calbiochem), at 37ºC for 16 165 
hours. γ-Secretase activity was assessed by measuring the levels of CTF-APP and the 166 
CTF of another γ-secretase substrate, the apolipoprotein E receptor 2 or ApoER2 [30] 167 
by Western blotting. 168 
 169 
170 
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Western blot  171 
Samples from cell lysates or brain extracts (30 to 50 µg of protein, equal amount in each 172 
lane) were resolved by electrophoresis on 10% SDS-polyacrylamide slab gels (SDS-173 
PAGE) under fully reducing conditions. Samples were denatured at 50°C for 15 minutes 174 
(PS1) or 98°C for 7 minutes (all the other proteins). For blue-native gel electrophoresis, 175 
samples were analyzed as previously described [31], and NativeMark™ Unstained 176 
Protein Standards (Life Technologies) were used as molecular weight markers. 177 
Following electrophoresis, proteins were blotted onto nitrocellulose membranes 178 
(Schleider & Schuell Bioscience GmbH, Dassel, Germany), and membranes were 179 
blocked with 5% nonfat milk. The membranes were probed with the following primary 180 
antibodies: anti-CTF-APP (Sigma-Aldrich), anti-CTF apolipoprotein E receptor 2 181 
(ApoER2; Abcam), anti-N-terminal PS1 (Calbiochem®, Merck KGaA, Darmstadt, 182 
Germany), anti- PEN2 (presenilin enhancer 2; from Sigma), anti-AChE antibody N-19 183 
(Santa Cruz Biotech), an anti-AChE antibody raised to the unique C-terminus of human 184 
AChE-R (also a generous gift from Dr. H. Soreq), and anti-glyceraldehyde 3-phosphate 185 
dehydrogenase (GAPDH) (Abcam, Cambridge, UK). Western blots for different 186 
antibodies were performed individually, to avoid re-using blots. The blots were then 187 
incubated with the corresponding secondary antibody conjugated to horseradish 188 
peroxidase and the signal was detected using SuperSignal West Femto 189 
Chemiluminescent Substrate (Thermo Scientific) in a Luminescent Image Analyzer 190 
LAS-1000 Plus (Fujifilm, Tokyo, Japan). For semi-quantitative analysis, the intensity of 191 
bands was measured by densitometry with the Science Lab Image Gauge v4.0 software 192 
provided by Fujiﬁlm.  Protein levels were normalized to GAPDH. 193 
 194 
195 
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PS1 immunoprecipitation  196 
Brain extracts were pre-cleared by incubation with protein A-Sepharose (Sigma-197 
Aldrich) for 2 hours at 4°C. Immunoprecipitations were performed at 4°C by first 198 
incubating 800 µg of protein overnight with the N-terminal PS1 antibody 98/1 (a 199 
generous gift form J. Culvenor, Department of Pathology, The University of Melbourne, 200 
Australia) previously coupled to protein A-Sepharose by dimethyl pimelimidate 201 
dihydrochloride (Sigma-Aldrich). Precipitated proteins were washed with PBS and 202 
eluted with 0.1M glycine buffer at pH 2.5. After pH neutralization, supernatants were 203 
denatured in Laemmli sample buffer at 97ºC for 7 min and subjected to SDS-204 
PAGE/Western blotting. Blots were incubated with the anti-AChE antibodies Ab31276 205 
and anti-AChE-R.  206 
 207 
RNA isolation and analysis of transcripts by qRT-PCR 208 
Total RNA was isolated from control CHO-PS70 cells or cells treated with eel-AChE 209 
using TRIzol Reagent in the PureLink™ Micro-to-Midi Total RNA Puriﬁcation System 210 
(Invitrogen) according to the manufacturer’s protocol. First-strand cDNAs were 211 
obtained by reverse transcription of 1 µg of total RNA using the High Capacity cDNA 212 
Reverse Transcription Kit (Applied Biosystems; life technologies Paisley, UK), according 213 
to the manufacturer’s instructions. Quantitative PCR amplification was performed in a 214 
StepOne™ Real-Time PCR System (Applied Biosystems) with TaqMan GenExpression 215 
Assays (Hs00997789 for PS1 and Hs03929097 for GAPDH) and TaqMan PCR Master 216 
Mix. Transcript levels for PS1 were calculated using the relative standard curve method 217 
normalized to GADPH. 218 
 219 
220 
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Co-localization of AChE and PS1 221 
CHO cells were transiently co-transfected with either 500 ng each of PS1-GFP (kindly 222 
provided by Dr. O. Berezovska; Massachusetts General Hospital, MA, USA) and 223 
AChE-T plasmids or 300 ng of each of PS1-GFP, AChE-T and PRiMA plasmids. Cells 224 
were fixed with 4% paraformaldehyde after 24 hours and immunostained for AChE 225 
using anti-AChE followed by an Alexa647-tagged secondary antibody (Molecular 226 
Probes, Inc, USA). Confocal images were taken with a SP5 confocal microscope (Leica 227 
Microsystems GmbH, Wetzlar, Germany) using a 63× objective (4× zoom). Laser 228 
power was kept low to avoid crossover between the two channels and to avoid pixel 229 
saturation. Confocal images were taken in multiple z planes (1micron apart). Analysis 230 
was performed using ImageJ software (v1.46g) [32]. Briefly, channels were thresholded 231 
to create a binary image and Manders’ co-efficients [33] were calculated using the 232 
JACoP JaCoP ImageJ plugin [34]. The Manders’ co-efficient corresponds to the 233 
fraction of AChE-positive pixels that are also positive for PS1. Images showing the 234 
pixels where the two channels co-localize were generated for the binary thresholded 235 
images using the Co-localization highlighter ImageJ plugin. 236 
 237 
Statistical analysis 238 
Data are expressed as means ± standard error of the mean (SEM). Data were analyzed 239 
using SigmaStat (Version 2.0; SPSS Inc.) by Student’s t-test (two tailed) or by one-way 240 
analysis of variance (ANOVA), followed by Tukey test for pair-wise comparisons. 241 
Statistical significance was designated as p < 0.05.242 
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Results 243 
Several AChE variants and isoforms interact with PS1  244 
We first investigated whether PS1 antibodies were able to co-precipitate the R and T 245 
variants, and G4 and G1 AChE-T species (Fig. 1). Human brain cortex samples were 246 
immunoprecipitated using an anti-PS1 antibody, and the bound fraction was analysed 247 
by Western blotting using different anti-AChE antibodies raised against different C-248 
terminal peptides of R and T AChE variants. Western blot analysis of the 249 
immunoprecipitates demonstrated that both AChE subunits, T and R, are potential PS1-250 
interacting proteins (Fig. 1A).  In agreement with our previous study (Silveyra et al., 251 
2008), ultracentrifugation in sucrose density gradients confirmed that both peaks 252 
corresponding to the major AChE G4 (tetramers of T subunits) and to the minor light 253 
forms (monomers of T, and potentially of R subunits) were decreased after 254 
immunoprecipitation with PS1 antibodies (Fig. 1B). 255 
 We next examined whether these AChE species influence PS1 levels (Fig. 2A). 256 
Over-expression of AChE-T and AChE-R in CHO cells, as monomeric forms, leads to a 257 
statistically significant increase in PS1 levels, compared to untransfected cells (Fig. 258 
2A). The differences between AChE-R (67 ±19%) and AChE-T increase (36 ±5%) on 259 
PS1 levels is not statistically significant (p= 0.18). Over-expression of AChE-T and 260 
AChE-R in the neuroblastoma cell line SH-SY5Y yield similar increases in PS1 levels 261 
(Supplementary Fig. 1). 262 
 263 
Influence of AChE in PS1 levels is not dependent on its catalytic activity 264 
All the molecular forms and variants of AChE have been demonstrated to be virtually 265 
equivalent in their catalytic activity [35,36]. We next examined whether the suppression 266 
of AChE catalytic activity affects its ability to modulate PS1 levels. As it has been 267 
previously shown that mutation of serine200 to valine abolishes detectable AChE activity 268 
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[27], we over-expressed site-directed mutants at serine200 for both AChE-T and AChE-269 
R. Over-expression of the inactive mutants, imAChE-T and imAChE-R resulted in an 270 
increase in AChE protein levels, as assessed by Western blotting, with no substantial 271 
increase in specific activity (Fig. 2B). However, both inactive mutants were able to 272 
induce an increase in PS1 levels (Fig. 2B), indicating that the modulatory capacity of 273 
AChE is exerted by a mechanism independent of its catalytic activity.  274 
 275 
Influence of AChE in PS1 levels is dependent on its subcellular localization 276 
The proline-rich membrane anchor (PRiMA) subunit is a small transmembrane protein 277 
that represents a limiting factor for the restricted localization of AChE into the plasma 278 
membrane.  It transforms monomeric AChE-T into a tetrameric AChE (G4)-PRiMA 279 
complex which anchors to the outer cell surface [37-39]. We examined if co-expression 280 
of the PRiMA subunit with AChE-T further affects PS1 levels. A CHO cell line over-281 
expressing AChE-T was co-transfected with the PRiMA subunit. As expected, cells 282 
over-expressing AChE and PRiMA produced significant amounts of G4 AChE in 283 
comparison with those over-expressing AChE only (Fig. 3A). Greater AChE activity 284 
was detected on the outer cell surface of intact (non-permeabilized) cultured cells over-285 
expressing AChE and PRiMA compared to cells transfected with AChE in the absence 286 
of PRiMA (Fig. 3B). Immunocytochemistry was also used to compare the distribution 287 
of PS1 and AChE, expressed as a monomer or as a tetrameric PRiMA-linked AChE. 288 
Immunofluorescence labelling of cells confirmed localization of PS1 to both the 289 
cytoplasmic region and the periphery (plasma membrane) (Fig. 3C, D), a finding 290 
consistent with previous reports by us and others [22, 40-42]. In the absence of PRiMA, 291 
AChE co-localized with PS1 mainly within the cytoplasmic region (80 ±7% of AChE 292 
pixels were also positive for PS1; Fig. 3C). In contrast, in the presence of PRiMA, 293 
AChE was, as expected, targeted to the plasma membrane with staining predominantly 294 
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localized to the cell periphery, with minor cytoplasmic co-localization with PS1 (only 295 
50 ±6% of AChE pixels were also positive for PS1; p= 0.03 versus AChE without 296 
PRiMA; Fig. 3D). The levels of PS1 in cells over-expressing AChE with PRiMA is 297 
higher than in cells over-expressing intracellular AChE alone, while over-expression of 298 
PRiMA alone fails to trigger noticeable change in PS1 levels (Fig. 3E). The PRiMA 299 
subunit is an accessory partner for the cellular disposition of AChE [39], at the plasma 300 
membrane always in the presence of AChE. In conclusion, the AChE induced increase 301 
in the levels of PS1 is further augmented by the presence of PRiMA at the plasma 302 
membrane. 303 
 304 
AChE increases PS1 protein and mRNA levels 305 
Our results indicate that the ability of AChE to induce an increase in PS1 levels is not 306 
dependent on its C-terminal (variant), oligomerization status (molecular form) or 307 
enzymatic activity. The most significant variable which determines how AChE 308 
influences PS1 levels is co-localization outside the plasma membrane. We therefore 309 
assessed if soluble AChE (a G4 species from Electrophorus electricus, eel-AChE) is 310 
able to modulate endogenous PS1 levels in untransfected CHO cells. After an 18 hour 311 
treatment with soluble eel-AChE, the levels of PS1 were significantly increased from 312 
0.5±1 to 34±1 mU/mL (Fig. 4A).  We next determined whether AChE influences the 313 
PS1 expression by measuring PS1 mRNA levels by qRT-PCR. Levels of the PS1 314 
transcripts were significantly increased (44 ±1%, p< 0.001) in eel-AChE treated cells 315 
compared to vehicle control cells (Fig. 4B). 316 
 317 
AChE inhibits γ-secretase activity 318 
Up-regulation of protein levels as a reaction to inhibition is a recognized phenomenon 319 
documented for several proteins [43,44], including AChE [17, 46,47]. To assess if 320 
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AChE-mediated PS1 up-regulation is linked to an inhibitory effect of AChE on γ-321 
secretase activity, we treated with eel-AChE CHO-PS70 cells, which stably overexpress 322 
wild-type human PS1 and wild-type APP and exhibit elevated γ-secretase activity [26]. 323 
The potential inhibitory effect of AChE on γ-secretase activity was monitored by 324 
measuring the accumulation of APP-CTF levels. Cells were treated for 18 hours with 325 
increasing amounts of eel-AChE, and levels of APP-CTF were determined in cellular 326 
extracts by Western blotting using an antibody raised against the APP C-terminal. A 327 
dose-dependent effect of AChE on γ-secretase activity was observed, with increased 328 
amount of APP-CTF in treated cells (Fig. 5A).  The inhibitory effect of AChE on γ-329 
secretase activity was then determined in membrane preparations isolated from CHO-330 
PS70 cells obtained as described elsewhere [29]. The presence of the γ-secretase 331 
complex in these membrane preparations was first confirmed by blue native-PAGE 332 
(Fig. 5B). A predominant PS1 immunoreactive band, with a molecular mass of ~450 333 
kDa (closed arrowhead), was detected together with other high molecular mass bands, 334 
corresponding to large γ-secretase complexes [48,49]. These bands were also 335 
immunoreactive for the γ-secretase component PEN2 (presenilin enhancer 2) [50].  To 336 
determine the effect of inhibition of γ-secretase activity on γ-secretase cleavage of APP, 337 
cell membranes were incubated at 37ºC for 16 hours in the absence or presence of N-338 
[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT), a well-339 
known γ-secretase inhibitor that targets PS1 [51]. The efficiency of 5 µM DAPT to 340 
inhibit γ-secretase activity was monitored by measuring the accumulation of APP-CTF 341 
in membrane preparations (Fig. 5C). Accumulation of APP-CTF was also observed in 342 
membrane preparations incubated with ~34±1 mU/mL of eel-AChE (Fig. 5C). The 343 
increased levels in the membrane preparation treated with eel-AChE of the CTF of 344 
ApoER2, another γ-secretase substrate [30], which was not over-expressed in CHO-345 
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PS70 cells, served to confirm the decrease in γ-secretase in presence of AChE (Fig. 5C). 346 
These results suggest that AChE may act as an inhibitor of γ-secretase activity. 347 
348 
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Discussion 349 
The cholinergic system has been shown to modulate APP metabolism [52,53] and 350 
AChE inhibitors affect amyloid production [54-56]. In turn, different reports have 351 
supported the possibility that Aβ may up-regulate AChE [57-61]. While characterization 352 
of the functional cross-talk between AChE/cholinergic neurotransmission and APP 353 
processing is of major interest, there is currently no consensus on the mechanisms 354 
which regulate these reciprocal interactions. Recent evidence demonstrates that 355 
cholinergic AChE can be down-regulated in neuronal cell lines by APP independently 356 
of secretase activity [62]. However, other studies have reported modulatory effects of 357 
AChE inhibitors on α-secretase  [63,64] and β-secretase [65-67]. Our previous studies 358 
have also described that AChE inhibitors are able to modulate PS1 levels [23].  359 
We have previously explored some of the potential consequences of the 360 
interaction between AChE and PS1, and demonstrated that AChE knockdown with 361 
siRNA, as well as AChE inhibition, decreased cellular PS1 levels; whereas AChE over-362 
expression exerted an opposing effect [23]. Our previous data also suggested that AChE 363 
does not exert its modulatory action on PS1 via a cholinergic mechanism, as the 364 
cholinergic agonist carbachol had no effect on PS1 [23]. Hence, the mechanisms 365 
employed by AChE to influence APP processing remained unclear. Our present study 366 
addresses how AChE influences PS1 expression by examining changes in PS1, at both 367 
protein and transcriptional levels, in several conditions where distinct AChE variant and 368 
molecular forms have been modulated. We first confirmed that AChE does not exert its 369 
modulatory action on PS1 via a cholinergic mechanism since mutant inactive variants 370 
also influence PS1 levels.  371 
Although all the AChE variants (R and T) and molecular forms (monomers and 372 
tetramers) tested can influence PS1 levels, the AChE species that triggered the major 373 
increase in PS1 levels was the PRiMA-linked AChE form. The PRiMA subunit restricts 374 
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localization of cholinergic tetrameric AChE to the outer plasma membrane. PS1 and 375 
AChE are located in the same intracellular compartments, including perinuclear 376 
compartments, but interestingly PRiMA has been shown to restrict AChE localization to  377 
the membrane of synapses [68-70]. Similarly, PS1 is targeted to the cell surface as an 378 
active γ-secretase complex [71].  However, the subcellular localization of biologically 379 
active γ-secretase is still a matter of controversy. Our studies demonstrate that AChE 380 
inhibits APP processing catalyzed by γ-secretase in both cells and membrane 381 
preparations. The possibility that AChE inhibits cleavage of APP by γ-secretase has 382 
been recently suggested [72]. Therefore, we postulated that, under non-pathological 383 
conditions, it is the cholinergic species of AChE which likely interacts with PS1, within 384 
the active γ-secretase complex, but by a mechanism independent of its catalytic activity. 385 
The mechanisms employed by AChE to influence APP processing remain 386 
unclear.  Besides the involvement of the catalytic activity of AChE, a direct effect based 387 
on protein-protein interaction also seems plausible. Indeed, AChE is much more than a 388 
cholinergic enzyme with distinct biological functions than merely hydrolysis of 389 
acetylcholine. In this context, excess of enzymatically inactivated brain AChE by 390 
transgenic over-expression have demonstrated different biological functions [13-15]. 391 
Native AChE is also present in non-cholinergic tissues and shares high sequence 392 
similarity with several neural cell adhesion proteins [73]. The presence of a 393 
cholinesterase-like domain in non-catalytic proteins structurally related to AChE may 394 
reflect its capacity for protein-protein interactions. This cholinesterase-like domain may 395 
have adhesive properties [74]. Therefore, AChE may inhibit APP processing by 396 
blocking access of γ-secretases to APP. We have recently demonstrated that γ-secretase 397 
is involved in the cleavage of PRiMA [75].  Neuroligin-1, a postsynaptic adhesion 398 
molecule whose extracellular domain is homologous to AChE, is also cleaved by γ-399 
secretase [76]. In general, the specific requirements for a γ-secretase substrate are 400 
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vague, and do not depend on a specific amino acid sequence or on endocytosis [77].  401 
More than 90 type-I integral membrane proteins are known to be potentially cleaved by 402 
γ-secretase [78], but which of those are “common” substrates for γ-secretase in 403 
physiological conditions remains unclear. We favor the hypothesis that AChE acts as an 404 
inhibitor of γ-secretase activity by interacting with PS1. Nonetheless, we can speculate 405 
that some potential substrates of γ-secretase, such as PRiMA from the AChE 406 
cholinergic complex, are not “common” substrates and only interact under specific 407 
physiological conditions, but which results in low catalytic efficiency. Likewise binding 408 
of AChE subunits to PS1 may restrict γ-secretase activity, similar to a negative feedback 409 
by end-product inhibition. Further extensive research is needed to determine how AChE 410 
blocks or interferes with PS1 and γ-secretase activity and which pool of AChE is 411 
involved in the process. 412 
In this study we report that an increase in AChE blocks γ-secretase activity. Up-413 
regulation in reaction to inhibition is a recognized phenomenon documented for several 414 
proteins [43,44], including AChE [17,45]. Our data suggest that inhibition of PS1 by 415 
AChE may initiate a feedback process that leads to up-regulation of PS1. Regarding the 416 
pathological condition, AChE activity (particularly the cholinergic specie) is decreased 417 
in the AD brain [28, 79-81], therefore impeding its ability to modulate γ-secretase 418 
activity. Interestingly, therapy with inhibitors of AChE demonstrated weak disease-419 
modifying effects in AD-treated patients, including modulation of APP expression and 420 
metabolism [63, 82-85]. As previously mentioned, the mechanisms employed by AChE 421 
inhibitors to influence APP processing remain unclear but may involve multiple 422 
mechanisms that vary according to the type of AChE inhibition. Specifically, how 423 
AChE inhibitors trigger a decrease in PS1 levels is unclear. However, it is important to 424 
note that the positive modulation of AChE inhibitors on APP failed to have a long-term 425 
effect in patients [83]. We propose that a limited response to AChE inhibitors may be 426 
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associated with AChE up-regulation in reaction to chronic inhibition, a feedback 427 
process that leads to accumulation of AChE in parallel with the lack of effect on PS1 428 
levels [23]. This phenomenon of AChE up-regulation, as a response to anti-AChE 429 
therapy, has been confirmed in patients under AChE inhibitor therapy [46,47,86]. 430 
Nonetheless, the subcellular localization of this new pool of AChE, and therefore the 431 
potential to interact with PS1, merits further investigation. 432 
In addition, under non-disease conditions AChE occurs as both active and 433 
inactive subunits [87,88], and the existence of inactive AChE has been demonstrated in 434 
brain [89]. We have recently shown by Western blotting and immunohistochemistry 435 
that a prominent pool of enzymatically inactive AChE protein existed in the AD brain 436 
[90]. The physiological significance of non-catalytic AChE in brain and how it is 437 
affected during pathology and treatment remain unexplored. 438 
In conclusion, our data concur with other reports suggesting the regulation of 439 
APP processing by AChE. This modulatory effect may involve cholinergic and non-440 
cholinergic mechanisms, independent of the catalytic activity of AChE. We demonstrate 441 
a modulation of PS1 by the AChE species via non-cholinergic mechanisms. We also 442 
provide evidence that γ-secretase inhibition could result in PS1 up-regulation which is 443 
of particular importance for AD therapy [91-93]. Elucidation of the mechanisms 444 
involved in the PS1-AChE interaction and reciprocal regulation are important for the 445 
optimization of current therapies based on AChE pharmacological interventions. 446 
447 
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Figure 1. PS1 interacts with AChE-T and AChE-R variants. (A) Co-precipitation of 748 
PS1 and AChE. Human brain extracts (frontal cortex from three non-demented subjects, 749 
mean age 58 ±3 years; one example is shown) were immunoprecipitated with anti-PS1 750 
antibody 98/1. PS1-immunoprecipitated proteins (PS1 IP) were immunoblotted with the 751 
indicated anti-AChE antibody specific for particular AChE variants (T and R). Extracts 752 
incubated with protein A-Sepharose, without antibody, were analyzed in parallel as 753 
negative controls (not shown). (B) The non-immunoprecipitated fraction was analyzed 754 
for molecular forms of AChE by sucrose gradient ultracentrifugation. Approximately 40 755 
fractions were collected from the bottom of each tube and assayed for AChE activity. 756 
Representative profiles of AChE molecular forms (tetramers: G4; and light dimers and 757 
monomers: G1+G2) prior (●) and after (○) immunoprecipitation are shown. Experiments 758 
were performed in triplicate. 759 
760 
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 762 
Figure 2. PS1 levels are regulated by AChE independent of its enzymatic activity. 763 
(A) Representative molecular profiles of AChE and immunodetection of PS1-NTF in 764 
CHO cells stably transfected with constructs carrying either the AChE-R or AChE-T 765 
cDNA. CHO cells stably transfected with a PCI vector served fas controls (Control). 766 
The results were confirmed in three independent experiments. The densitometric 767 
quantification of PS1-NTF immunoreactivity is represented. Protein levels were 768 
normalized to glyceraldehyde 3-phosphate deydrogenase (GADPH).  (B) PS1 769 
immunodetection and densitometric quantification in cells transfected with the inactive 770 
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form of AChE-R (imAChE-R) and AChE-T (imAChE-T). Immunoblots with the anti-771 
AChE antibody N19 antibody confirmed the expression of equal amounts of imAChE-R 772 
and imAChE-T in transfected cells. Columns represent mean ± SEM from three 773 
different experiments (n= 12 for each condition). Representative immunoblots are 774 
shown.  **p < 0.01 and *p< 0.05, significant difference from the control group. 775 
776 
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 777 
 778 
Figure 3. Regulation of PS1 levels by tetrameric PRiMA-linked AChE located in 779 
the plasma membrane. (A) Representative profiles of AChE in CHO cells stably 780 
transfected with AChE-T cDNA without (●; AChE-T) and with PRiMA co-expression 781 
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(●; AChE-T+PRiMA) (G4=tetramers; G1+G2=monomers and dimers). The results were 782 
confirmed in four independent determinations. (B) AChE activity was also assayed 783 
directly in plasma membranes from cultured cells transfected with AChE-T in presence 784 
or absence of PRiMA cDNA. The inner dark columns represent AChE activity levels 785 
after treatment with the AChE inhibitor tacrine (10µM). (C, D) AChE-T is transported 786 
from the cytoplasm to the cell periphery in the presence of PRiMA. Representative 787 
images of CHO cells transiently co-expressing PS1 and AChE-T (C), or PS1, AChE-T 788 
and PRiMA (D). PS1; PS1-GFP (488 nm) channel, AChE; Anti-AChE N19 (647 nm) 789 
channel. Overlay; overlay of 488 nm and 647 nm channels. Co-localization; channel 790 
overlay with pixels positive for both PS1 and AChE, marked in white. M; Mander’s co-791 
localization co-efficient. Localization of PS1 and AChE-T in the absence of PRiMA is 792 
observed mainly in the cytoplasmic region (C). The mean number of AChE-T pixels co-793 
localizing with PS1 was 79.5% (n=3). Cells expressing AChE-T+PRiMA and PS1 show 794 
localization of AChE at the cell periphery with only 50.1% of AChE pixels co-localized 795 
with PS1 (n=3). (E) Immunodection and densitometric quantification of PS1-NTF 796 
(normalized to GADPH) in CHO cells transfected with AChE-T, AChE-T+PRiMA or 797 
PRiMA alone. Columns represent mean ± SEM from two different experiments (n= 10 798 
for each condition). Significantly different (p < 0.05) from cells over-expressing 799 
PRiMA alone (*), or from the AChE-T cells (†). 800 
801 
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Figure 4. The presence of exogenous AChE increases PS1 expression. CHO cells 804 
were treated for 18 hours with AChE from Electrophorus electricus (eel-AChE; at 805 
~34±1 mU/mL of enzymatic activity) or saline (Control). (A) Cell extracts were 806 
analyzed by Western blot with an anti-N-terminal PS1 antibody. Equivalent amounts of 807 
protein were loaded in each lane and GAPDH was used as a loading control.  An 808 
increase in PS1 immunoreactivity was observed in cells treated with eel-AChE (B) 809 
Messenger RNA levels of the PS1 transcript were measured by qRT-PCR from cell 810 
extracts. Values were calculated using relative standard curves and normalized to 811 
GAPDH obtained from the same cDNA preparations. mRNA levels were significantly 812 
increased in cells treated with eel-AChE. Data represent mean ± SEM from a minimum 813 
of 15 independent determinations from three independent experiments. *p < 0.001. 814 
815 
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Figure 5. Inhibition of PS1/γ-secretase processing of C-terminal fragments of APP 818 
by AChE. (A) Dose-dependent effect of soluble AChE from Electrophorus electricus 819 
(eel-AChE) on APP processing. CHO cells were treated with 0 (saline; Control), ~9±1 820 
mU/mL (1×), ~17±1 mU/mL (2×), ~34±1 mU/mL (5×) or ~70±1 mU/mL (10×) of 821 
active eel-AChE. Cell extracts blotted with a C-terminal anti-APP antibody 822 
demonstrated APP CTF accumulation in treated cells as a result of the inhibition of γ-823 
secretase processing. (B) CHO cells over-expressing PS1 were homogenized and 824 
membranes isolated by sequential centrifugation (see Material & Methods). γ-Secretase 825 
complexes were characterized by blue native-PAGE using an anti-PS1 antibody. 826 
Complexes of different molecular mass were detected. Similar immunoreactive bands 827 
(arrowheads) were detected for PEN2, a subunit of the γ-secretase complex. (C) γ-828 
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Secretase cleavage of endogenous APP in membrane preparations of CHO cells was 829 
assessed in the presence of ~34±1 mU/mL of eel-AChE. γ-secretase activity was 830 
inhibited in cells treated with 5 µM of the γ-secretase inhibitor DAPT. Data represent 831 
the percentage relative to control cells. The results were confirmed in two independent 832 
experiments (n= 8 determinations). *p < 0.05. 833 
834 
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Supplementary Figure 1. Effect of the AChE over-expression on PS1 levels in SH-837 
SY5Y cells.  Immunodetection and densitometric quantification of PS1-NTF for AChE-838 
R or AChE-T transfected, and control cells transfected with a PCI vector. Protein levels 839 
were normalized to glyceraldehyde 3-phosphate deydrogenase (GADPH).  Data 840 
represent percentage relative to control cells, expressed as means ± SEM of 10 841 
independent determinations from at two different experiments. *p < 0.05. 842 
